Invitae Stock News

Invitae (NYSE:NVTA) is scheduled to announce Q4 earnings results on Thursday, February 24th, after market close.The consensus EPS Estimate is -$0.77 (-22.2% Y/Y) and the consensus…

Biotech stock extended lower for a second straight week as risk aversion continued to pressure stocks amid geopolitical tensions and macroeconomic worries. On the regulatory front, the Food and Drug A

- New in-vitro diagnostic kits help patients fight cancer in the EU - Invitae (NYSE: NVTA), a leading medical genetics company, today announced the availability of FusionPlex Dx ® and LiquidPlex Dx ™ in Europe, part of its industry-leading Anchored Multiplex PCR chemistry in-vitro diagnostic (IVD) products. Invitae is delivering essential high quality innovation for precision oncology in the fight against cancer. With this announcement, Invitae provides the highest quality CE-IVD products to enable European pathologists and oncologists to efficiently provide vital information, in a timely manner, to guide cancer therapy for patients. "This is a major step toward our mission to bring comprehensive genetic information into mainstream medicine," said Vishal Sikri, President of Oncology at Invitae. "Our best in class FusionPlex ® and LiquidPlex ™ tests will enable more patients access to the right cancer therapies at the right time, which is especially critical in Europe where the

Invitae Corporation (NYSE: NVTA), a leading medical genetics company, today announced that it will report its fourth quarter and full year 2021 financial results on Thursday, February 24, 2022, and will host a conference call and webcast that day at 4:30 p.m. Eastern / 1:30 p.m. Pacific to discuss its financial results and recent highlights. To access the conference call, please register at the link below: https://conferencingportals.com/event/DqFqYhVe Upon registering, each participant will be provided with call details and a conference ID. Reminders will also be sent to registered participants via email. The live webcast of the call and slide deck may be accessed here or by visiting the investors section of the company''s website at ir.invitae.com . A replay of the webcast will be available shortly after the conclusion of the call and will be archived on the company''s website. About Invitae Invitae Corporation (NYSE: NVTA) is a leading medical genetics company, whose mission is

Invitae (NVTA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Brooks (AZTA) delivered earnings and revenue surprises of 50% and 3.72%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

SAN FRANCISCO, Feb. 3, 2022 /PRNewswire/ --  Invitae Corporation (NYSE: NVTA), a leading medical genetics company, today announced that members of its management team will participate in virtual fir

Invitae (NVTA) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising e

Invitae (NVTA) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising e

Bargain-hunting investors have good reason to be tempted, but a steep sell-off alone isn't enough of a bullish argument.

Bargain-hunting investors have good reason to be tempted, but a steep sell-off alone isn't enough of a bullish argument.

The stock market and bond market remain historically overvalued today, however, the almost all-encompassing bubble has started to break. Learn more here.

We give an overview of the four genetic testing companies 23andMe, Ancestry, Color, and Invitae that are racing to the forefront of healthcare.

Invitae Corp (NVTA) shares closed 0.9% lower than its previous 52 week low, giving the company a market cap of $2B. The stock is currently down 22.3% year-to-date, down 75.1% over the past 12 months, and up 32.8% over the past five years. This week, the Dow Jones Industrial Average fell 0.3%, and the S&P 500 rose 0.6%. Trading Activity Trading volume this week was 9.0% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.7. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 50.1% The company's stock price performance over the past 12 months lags the peer average by 266.7% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

Invitae Corporation (NVTA) CEO Sean George on JPMorgan 40th Annual Healthcare Conference (Transcript)